BG105214A - Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders - Google Patents

Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders

Info

Publication number
BG105214A
BG105214A BG105214A BG10521401A BG105214A BG 105214 A BG105214 A BG 105214A BG 105214 A BG105214 A BG 105214A BG 10521401 A BG10521401 A BG 10521401A BG 105214 A BG105214 A BG 105214A
Authority
BG
Bulgaria
Prior art keywords
glucocorticoid
receptor ligands
treatment
hormone receptor
metabolic disorders
Prior art date
Application number
BG105214A
Other languages
Bulgarian (bg)
English (en)
Inventor
Theresa Apelqvist
Patrick Goede
Erik Holmgren
Original Assignee
Karo Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio Ab filed Critical Karo Bio Ab
Publication of BG105214A publication Critical patent/BG105214A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG105214A 1998-08-05 2001-02-02 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders BG105214A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816935.2A GB9816935D0 (en) 1998-08-05 1998-08-05 Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
PCT/IB1999/001447 WO2000007972A1 (en) 1998-08-05 1999-08-04 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
BG105214A true BG105214A (en) 2001-12-29

Family

ID=10836671

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105214A BG105214A (en) 1998-08-05 2001-02-02 Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders

Country Status (26)

Country Link
US (1) US6492424B1 (cg-RX-API-DMAC10.html)
EP (1) EP1102739B1 (cg-RX-API-DMAC10.html)
JP (1) JP2002522407A (cg-RX-API-DMAC10.html)
KR (1) KR20010072113A (cg-RX-API-DMAC10.html)
CN (1) CN1311767A (cg-RX-API-DMAC10.html)
AT (1) ATE238267T1 (cg-RX-API-DMAC10.html)
AU (1) AU753376B2 (cg-RX-API-DMAC10.html)
BG (1) BG105214A (cg-RX-API-DMAC10.html)
BR (1) BR9912742A (cg-RX-API-DMAC10.html)
CA (1) CA2339194A1 (cg-RX-API-DMAC10.html)
DE (1) DE69907210T2 (cg-RX-API-DMAC10.html)
DK (1) DK1102739T3 (cg-RX-API-DMAC10.html)
ES (1) ES2193730T3 (cg-RX-API-DMAC10.html)
GB (1) GB9816935D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0103222A3 (cg-RX-API-DMAC10.html)
ID (1) ID28805A (cg-RX-API-DMAC10.html)
IL (1) IL141106A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA01001047A (cg-RX-API-DMAC10.html)
NO (1) NO20010610L (cg-RX-API-DMAC10.html)
PL (1) PL345824A1 (cg-RX-API-DMAC10.html)
SE (1) SE1102739T5 (cg-RX-API-DMAC10.html)
SI (1) SI20579A (cg-RX-API-DMAC10.html)
SK (1) SK942001A3 (cg-RX-API-DMAC10.html)
TR (1) TR200100274T2 (cg-RX-API-DMAC10.html)
WO (1) WO2000007972A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200100832B (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051971A1 (en) 1999-03-01 2000-09-08 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
GB9928805D0 (en) * 1999-12-07 2000-02-02 Karobio Ab Compounds active at the Glucocorticoid and Thyroid Hormone Receptors
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
AU2001216038A1 (en) * 2000-11-14 2002-05-27 Alcon Laboratories Inc. Treatment of glaucoma and ocular hypertension
GB0029102D0 (en) 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
GB0029100D0 (en) * 2000-11-29 2001-01-10 Karobio Ab Compounds active at the glucocorticoid receptor
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
US6777442B2 (en) * 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
GB0111861D0 (en) 2001-05-15 2001-07-04 Karobio Ab Novel compounds
KR20040027927A (ko) 2001-08-24 2004-04-01 카로 바이오 아베 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
DE60208132T2 (de) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
WO2003026632A2 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
CA2473162A1 (en) 2002-01-30 2003-08-07 Kissei Pharmaceutical Co., Ltd. Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
AU2002951977A0 (en) 2002-10-10 2002-10-24 Leo Engineering Pty Ltd Improvements to two-part vessels
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
WO2009129225A1 (en) * 2008-04-15 2009-10-22 Osteogenex, Inc. Compounds and methods for altering bone growth
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
WO1999063976A2 (en) * 1998-06-08 1999-12-16 Karo Bio Ab Liver-selective glucocorticoid antagonist for treating diabetes

Also Published As

Publication number Publication date
WO2000007972A1 (en) 2000-02-17
SE1102739T5 (cg-RX-API-DMAC10.html) 2003-09-16
SK942001A3 (en) 2001-12-03
AU753376B2 (en) 2002-10-17
ZA200100832B (en) 2001-10-31
KR20010072113A (ko) 2001-07-31
HUP0103222A3 (en) 2002-12-28
NO20010610D0 (no) 2001-02-05
EP1102739A1 (en) 2001-05-30
DE69907210T2 (de) 2004-02-19
BR9912742A (pt) 2001-05-02
AU5188199A (en) 2000-02-28
JP2002522407A (ja) 2002-07-23
CN1311767A (zh) 2001-09-05
ID28805A (id) 2001-07-05
IL141106A0 (en) 2002-02-10
ES2193730T3 (es) 2003-11-01
TR200100274T2 (tr) 2001-09-21
ATE238267T1 (de) 2003-05-15
EP1102739B1 (en) 2003-04-23
US6492424B1 (en) 2002-12-10
SE1102739T3 (cg-RX-API-DMAC10.html) 2003-08-12
HUP0103222A2 (hu) 2002-01-28
GB9816935D0 (en) 1998-09-30
CA2339194A1 (en) 2000-02-17
DE69907210D1 (de) 2003-05-28
PL345824A1 (en) 2002-01-14
MXPA01001047A (es) 2002-09-02
NO20010610L (no) 2001-04-04
SI20579A (sl) 2001-12-31
DK1102739T3 (da) 2003-08-18

Similar Documents

Publication Publication Date Title
ZA200100832B (en) Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders.
CA2294098A1 (en) Novel thyroid receptor ligands and method
Hansen et al. Glucagon-like peptide-1-(7–36) amide is transformed to glucagon-like peptide-1-(9–36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
WO2000039077A3 (en) Thyroid receptor ligands
ATE196252T1 (de) Behandlung von hornincontinenz durch verwendung von (s)-oxybutynin und (s)-desethyloxybutynin
WO1995018616B1 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
MY140525A (en) Pharmaceutical uses for alpha2delta ligands
HUP0102656A2 (hu) Elhízás és egyéb rendellenességek kezelésében hasznos, neuropeptid Y Y5 receptor ligandumaiként szolgáló N-helyettesített aminotetralinok és ezeket tartalmazó gyógyszerkészítmények
CZ85395A3 (en) Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon
FR2697252B1 (fr) Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
AU2251901A (en) Methods and compounds for inhibiting MRP1
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
WO2004066929A3 (en) Cycloalkyl containing anilide ligands for the thyroid receptor
Stoeckel et al. Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability
TW200507836A (en) Therapeutic agents
CA2053820A1 (en) Method of Inhibiting Metabolism of Cholesterol
GB0215978D0 (en) Novel compounds
DE69905877D1 (de) Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
HK95697A (en) 5-HT1-like receptor agonist for rectal administration
HUT64309A (en) Process for production pharmaceutical preparations having benzazepine compounds as effective substance and the new effective substance
Dhar et al. Approaches to short-acting neuromuscular blocking agents: Nonsymmetrical bis-tetrahydroisoquinolinium mono-and diesters
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
AU2224795A (en) Ameliorant or remedy for paraneoplastic syndrome
Gourdji et al. Effects of VIP on prolactin and growth hormone secretion by GH cells. regulation by peripheral hormone